281 results on '"Bataller, Alex"'
Search Results
2. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm
3. Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort
4. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study
5. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study
6. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
7. Germ line variants in patients with acute myeloid leukemia without a suspicion of hereditary hematologic malignancy syndrome
8. Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan
9. TP53 Y220C mutations in patients with myeloid malignancies
10. Mutation patterns and prognostic implications in acute myeloid leukemia with chromosomal 7 deletions.
11. A retrospective comparison of abbreviated course “7+7” vs standard hypomethylating agent plus venetoclax doublets in older/unfit patients with newly diagnosed acute myeloid leukemia.
12. Advances in the management of higher-risk myelodysplastic syndromes: future prospects
13. CD34+CD19−CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies
14. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol
15. Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1
16. A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL
17. NPM1‐mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage.
18. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation.
19. Engraftment characterization of risk-stratified AML in NSGS mice
20. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups
21. Age and comorbidity are determining factors in the overall and relative survival of patients with follicular lymphoma
22. Mandibular movement analisys by means of a kinematic model applied to the design of oral appliances for the treatment of obstructive sleep apnea
23. Integrative single-cell multi-omics of CD19-CARposand CARnegT cells suggest drivers of immunotherapy response in B-cell neoplasias
24. 3083 – SINGLE CELL MULTIOMIC ANALYSIS OF CLONAL AND TRANSCRIPTIONAL PROGRAMS OF CD19 CAR T CELLS IN THE IMMUNOTHERAPY RESPONSE
25. Integrative single‐cell expression and functional studies unravels a sensitization to cytarabine‐based chemotherapy through HIF pathway inhibition in AML leukemia stem cells.
26. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants
27. AML-207 Characteristics and Outcomes of Patients With Acute Myeloid Leukemia and DDX41 Mutation
28. MDS-208 Characteristics and Outcomes of Patients With Myelodysplastic Syndrome and DDX41 Mutation
29. POSTER: MDS-208 Characteristics and Outcomes of Patients With Myelodysplastic Syndrome and DDX41 Mutation
30. Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF
31. POSTER: AML-207 Characteristics and Outcomes of Patients With Acute Myeloid Leukemia and DDX41 Mutation
32. Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineage-directed therapies
33. P728: EVALUATION OF IPSS-M IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
34. P743: CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
35. P730: EVOLUTION OF IPSS-M RISK CATEGORIES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM DIAGNOSIS TO HYPOMETHYLATING AGENT FAILURE
36. P532: KINETICS AND PROGNOSTIC VALUE OF MEASURABLE RESIDUAL DISEASE (MRD) IN PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH VENETOCLAX IN COMBINATION WITH HYPOMETHYLATING AGENTS.
37. P500: SUPERIOR OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AMONG PATIENTS ≥ 60 YEARS TREATED WITH CLADRIBINE, LOW DOSE CYTARABINE PLUS VENETOCLAX FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
38. S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
39. P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE
40. WinMecC: Software for the Analysis and Synthesis of Planar Mechanisms
41. Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis
42. The role of TGFβ in hematopoiesis and myeloid disorders
43. Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation
44. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial
45. Phase II study of cladribine, idarubicin, and ara‐C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.
46. Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations
47. PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia
48. Outcomes of patients with therapy‐related myeloid neoplasms after treatment with poly( ADP ‐ribose) polymerase proteins inhibitors for solid tumours
49. Performance of IPSS‐M in patients with myelodysplastic syndrome after hypomethylating agent failure.
50. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.